Ciclop Tablet
Ticlopidine Hydrochloride
250mg
Zydus Pharmaceuticals
| Pack size | 1 |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 12.06 NPR |
Indications
Ciclop Tablet is used for:
Hereditary hemorrhagic telangiectasia, Intermittent claudication, Ischaemic heart disease
Adult Dose
Oral
Prophylaxis of thrombotic stroke; Ischaemic heart disease; Intermittent claudication
Adult: >18 yr: 250 mg bid.
Prophylaxis of subacute stent occlusion after intracoronary stenting
Adult: >18 yr: 250 mg bid for 4 wk, in conjunction with aspirin, starting at the time of stent placement.
Hepatic impairment: Severe: contraindicated.
Child Dose
<18 years old: safety & efficacy not established
Renal Dose
Renal impairment: Dose reduction or discontinuance if haemorrhagic or haematopoietic complications occur.
Administration
Should be taken with food.
Contra Indications
Pre-existing or history of blood dyscrasias; haemostatic disorder or active pathological bleeding (eg. bleeding peptic ulcer, intracranial bleeding); severe hepatic dysfunction. Hypersensitivity. Lactation.
Precautions
Patients with increased risk of bleeding from trauma, surgery or pathological disorder. Moderate to severe renal impairment. May need to stop therapy 10-14 days before elective surgery. Full blood counts should be performed prior to therapy and every 2 wk during the first 3 mth of treatment. Pregnancy.
Lactation: not known whether excreted in breast milk, discontinue drug or do not nurse
Pregnancy-Lactation
Interactions
Reduced clearance with cimetidine; corticosteroid may antagonise effects on bleeding time. Avoid concurrent use with clopidogrel.
Potentially Fatal: Risk of haemorrhage increased with NSAIDs and oral anticoagulants; decreased metabolism of theophylline, phenytoin and bupropion.
Adverse Effects
Side effects of Ticlopidine Hydrochloride :
>10%
Diarrhea (12.5%)
1-10%
Elevated alkaline phosphatase (7.6%),Nausea (7%),Dyspepsia (7%),Rash (5%),GI pain (3.7%),Elevated AST/SGOT (3.1%),Neutropenia (2.4%),Purpura (2.2%),Vomiting (1.9%),Flatulence (1.5%),Pruritus (1.3%),Dizziness (1%),Abnormal LFTs (1%),Anorexia (1%)
<1%
Agranulocytosis,Aplastic anemia,Pancytopenia,TTP
Potentially Fatal: Neutropenia, agranulocytosis, thrombotic thrombocytopenic purpura and aplastic anaemia.
Mechanism of Action
Ticlopidine inhibits adenosine diphosphate-mediated platelet aggregation.
Note
Ciclop 250mg Tablet manufactured by Zydus Pharmaceuticals. Its generic name is Ticlopidine Hydrochloride. Ciclop is availble in Nepal.
Farmaco Nepal drug index information on Ciclop Tablet is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.